Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

Table 2 Multivariable analysis of factors associated with good or moderate EULAR response at 1 year (n = 172)

	OR	95% CI	p
Age > 49 years	0.82	0.35–1.89	0.64
Sex (female)	1.52	0.51–4.53	0.45
Education level
Primary school	0.29	0.08–1.03	0.06
Middle school	0.53	0.19–1.46	0.22
High school	ref	–	0.23
University	0.73	0.25–2.15	0.56
Smoking status
Current smoking	ref	–	0.70
Past smoking	0.82	0.24–2.77	0.75
Never smoked	1.23	0.42–3.65	0.71
DAS28 level			0.71
Tender joint count ≥ 10	1.21	0.47–3.14	0.68
Swollen joint count ≥ 7	0.94	0.33–2.69	0.91
Rheumatologist global assessment ≥ 66/100 (VAS)	1.15	0.51–2.58	0.74
Early DMARD treatment¹	2.41	1.07–5.42	0.03
HAQ-DI ≥ 1	1.41	0.67–2.98	0.37
ESR ≥ 15 mm/h	1.42	0.66–3.03	0.37
CRP level ≥ 7 mg/l	0.71	0.32–1.61	0.42
mTSS (per unit)	1.00	0.94–1.07	0.96
mTSS	0.87	0.30–2.52	0.79

CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, mTSS van der Heijde-modified total Sharp score, VAS visual analog scale, OR odds ratio, 95% CI 95% confidence interval
¹Within 3 months after the first joint swelling

ISSN: 1478-6362